ISR's, SARS-CoV-2 dry powder nasal - vaccine booster candidate, ISR52, demonstrates superior immune response, in mouse model challenge studies compared to subcutaneous injection of this vaccine.
ISR Immune System Regulation Holding AB (Publ.) styrelseledamot Anders Olsson Fogelberg lämnar sitt uppdrag av hälsoskäl.
Nasdaqs avnoteringsbeslut påverkar inte ingångna avtal rörande finansiering för ISR Holding AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
